Candel Therapeutics, Inc. (NASDAQ: CADL) announced overall survival data from a phase II study evaluating its lead investigational adenovirus immunotherapy candidate, CAN-2409 plus valacyclovir (prodrug), together with standard of care (SoC) in patients with stage III/IV non-small cell lung cancer (NSCLC) who are non-responsive to immune checkpoint inhibitor therapy. Data from the study showed that treatment with two administrations of CAN-2409 plus valacyclovir led to a median overall survival of 20.6 months in NSCLC patients whose disease had progressed despite receiving prior anti-PD-1 treatment. The data will be presented at the annual meeting of the American Society of Clinical Oncology, which is scheduled to be held from May 31 to Jun 4, 2024. Per the press release, the above mentioned data was in context to earlier published data, which demonstrated a median overall survival of 11.6 months observed with standard-of-care docetaxel-based chemotherapy in a similar patient population. Importantly, treatment with CAN-2409 exhibited a favorable safety and tolerability profile in NSCLC patients as of the data cut-off date. Despite the upbeat data, shares of Candel were ...